Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Tislelizumab × Gastrointestinal × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 5275 Pancreatic Neoplasms 3174 Carcinoma, Hepatocellular 2907 Stomach Neoplasms 2722 Colonic Neoplasms 2065 Rectal Neoplasms 1955 Esophageal Neoplasms 1603 Liver Neoplasms 1105 Neoplasms 1057 Breast Neoplasms 933 Neoplasm Metastasis 755 Carcinoma, Non-Small-Cell Lung 694 Lung Neoplasms 644 Cholangiocarcinoma 638 Gastrointestinal Neoplasms 592 Ovarian Neoplasms 552 Esophageal Squamous Cell Carcinoma 523 Prostatic Neoplasms 426 Melanoma 397 Biliary Tract Neoplasms 385 Head and Neck Neoplasms 326 Gastrointestinal Stromal Tumors 293 Uterine Cervical Neoplasms 292 Carcinoma, Renal Cell 287 Adenocarcinoma Of Esophagus 282 Barrett Esophagus 278 Sarcoma 272 Gallbladder Neoplasms 250 Squamous Cell Carcinoma of Head and Neck 247 Anus Neoplasms 247

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04906044 2023-11-18

STARS-RC03

The First Hospital of Jilin University

Phase 1 Active not recruiting

Gastrointestinal

Tislelizumab

Data powered by HemOnc (CC BY 4.0) Colophon ⚡